IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid …
In a research report released Tuesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) with an $8.00 price …
Intellipharmaceutics Intl Inc (USA) (NASDAQ:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid …
Brean Capital analyst Jonathan Aschoff weighed in today with a few insights on IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI), after the company provided an update on the progress of the product …
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic …
Intellipharmaceutics International Inc. (Nasdaq:IPCI), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid …
hares of IntelliPharmaceutics International (NASDAQ: IPCI) saw a nearly 6% increase in trading on Tuesday, February 2nd following the company’s announcement that it has signed …
Brean Capital analyst Jonathan Aschoff came out today with a research note on Intellipharmaceutics (NASDAQ:IPCI), as the company announced a licensing agreement with Teva …
Maxim’s healthcare analyst Jason Kolbert is weighing in with an update on Intellipharmaceutics International (NASDAQ:IPCI), as the company announced the it has signed a license agreement …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Intellipharmaceutics International (NASDAQ:IPCI) with a $7 price target, …